NCT00366106

Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma

A Phase II, Open Label Study Evaluating an Alternative Schedule of Velcade/Dexamethasone Plus Doxil in the Treatment of Multiple Myeloma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Accelerated Community Oncology Research Network · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The current study is being conducted to evaluate the possibility that a different schedule of bortezomib, doxorubicin HCl liposome, and dexamethasone might decrease the incidence of peripheral neuropathy yet maintain similar efficacy and allow maintenance of bortezomib dosing for a longer period.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	bortezomib	Patients will be treated with bortezomib at 1.3mg/m\^2 on Days 1, 4, 15, and 18 every 28 days (cycle).
DRUG	dexamethasone	Dexamethasone tablets will be given at 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days (cycle).
DRUG	doxorubicin HCl liposome	Patients will receive intravenous doxorubicin HCl liposome injection given at 30 mg/m\^2 on Day 4 every 28 days (cycle).

Timeline

• Start date: 2006-07-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2006-08-18
• Last updated: 2012-04-06
• Results posted: 2012-04-05

Locations

15 sites across 1 country: United States